These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 9748598

  • 1. Secondary leukemias induced by topoisomerase-targeted drugs.
    Felix CA.
    Biochim Biophys Acta; 1998 Oct 01; 1400(1-3):233-55. PubMed ID: 9748598
    [Abstract] [Full Text] [Related]

  • 2. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
    Broeker PL, Super HG, Thirman MJ, Pomykala H, Yonebayashi Y, Tanabe S, Zeleznik-Le N, Rowley JD.
    Blood; 1996 Mar 01; 87(5):1912-22. PubMed ID: 8634439
    [Abstract] [Full Text] [Related]

  • 3. Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.
    Mathew S, Head D, Rubnitz JE, Raimondi SC.
    Genes Chromosomes Cancer; 2000 Jun 01; 28(2):227-32. PubMed ID: 10825008
    [Abstract] [Full Text] [Related]

  • 4. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
    Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, Stanulla M, Schrappe M, Creutzig U, Ritter J, Leis T, Jacobs U, Harbott J, Beck JD, Rascher W, Repp R.
    Genes Chromosomes Cancer; 2003 Apr 01; 36(4):393-401. PubMed ID: 12619163
    [Abstract] [Full Text] [Related]

  • 5. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
    Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson AE, Lange BJ.
    Blood; 1995 Jun 01; 85(11):3250-6. PubMed ID: 7756657
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.
    Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J, Zeleznik-Le N.
    Blood; 1997 Jul 15; 90(2):535-41. PubMed ID: 9226152
    [Abstract] [Full Text] [Related]

  • 8. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11).
    Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M.
    Leukemia; 1995 Aug 15; 9(8):1305-12. PubMed ID: 7643617
    [Abstract] [Full Text] [Related]

  • 9. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region.
    Strissel PL, Strick R, Rowley JD, Zeleznik-Le NJ.
    Blood; 1998 Nov 15; 92(10):3793-803. PubMed ID: 9808573
    [Abstract] [Full Text] [Related]

  • 10. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.
    Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, Megonigal MD, Williams WR, Nowell PC, Felix CA.
    Proc Natl Acad Sci U S A; 2001 Aug 14; 98(17):9802-7. PubMed ID: 11493704
    [Abstract] [Full Text] [Related]

  • 11. Polymorphisms in the MLL breakpoint cluster region (BCR).
    Echlin-Bell DR, Smith LL, Li L, Strissel PL, Strick R, Gupta V, Banerjee J, Larson R, Relling MV, Raimondi SC, Hayashi Y, Taki T, Zeleznik-Le N, Rowley JD.
    Hum Genet; 2003 Jul 14; 113(1):80-91. PubMed ID: 12665971
    [Abstract] [Full Text] [Related]

  • 12. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
    Smith MA, Rubinstein L, Ungerleider RS.
    Med Pediatr Oncol; 1994 Jul 14; 23(2):86-98. PubMed ID: 8202047
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.
    Lovett BD, Strumberg D, Blair IA, Pang S, Burden DA, Megonigal MD, Rappaport EF, Rebbeck TR, Osheroff N, Pommier YG, Felix CA.
    Biochemistry; 2001 Feb 06; 40(5):1159-70. PubMed ID: 11170441
    [Abstract] [Full Text] [Related]

  • 15. Leukemias related to treatment with DNA topoisomerase II inhibitors.
    Felix CA.
    Med Pediatr Oncol; 2001 May 06; 36(5):525-35. PubMed ID: 11340607
    [Abstract] [Full Text] [Related]

  • 16. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.
    Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J.
    Br J Haematol; 2001 Sep 06; 114(3):539-43. PubMed ID: 11552977
    [Abstract] [Full Text] [Related]

  • 17. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
    Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ, Felix CA.
    Proc Natl Acad Sci U S A; 2000 Mar 14; 97(6):2814-9. PubMed ID: 10706619
    [Abstract] [Full Text] [Related]

  • 18. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site.
    Slater DJ, Hilgenfeld E, Rappaport EF, Shah N, Meek RG, Williams WR, Lovett BD, Osheroff N, Autar RS, Ried T, Felix CA.
    Oncogene; 2002 Jul 11; 21(30):4706-14. PubMed ID: 12096348
    [Abstract] [Full Text] [Related]

  • 19. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing.
    Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD, Carroll M, Liu M, Osheroff N, Cheung NK, Slater DJ, Ried T, Knutsen T, Blair IA, Felix CA.
    Oncogene; 2003 Nov 20; 22(52):8448-59. PubMed ID: 14627986
    [Abstract] [Full Text] [Related]

  • 20. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors.
    Aplan PD, Chervinsky DS, Stanulla M, Burhans WC.
    Blood; 1996 Apr 01; 87(7):2649-58. PubMed ID: 8639880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.